Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

  • STATUS
    Recruiting
  • participants needed
    390
  • sponsor
    Jiangsu HengRui Medicine Co., Ltd.
Updated on 19 February 2024
cancer
measurable disease
paclitaxel
monoclonal antibodies
monoclonal antibody therapy
chemoradiotherapy
shr-1210
esophageal cancer
squamous cell carcinoma of esophagus
antibody therapy
camrelizumab
cisplatin

Summary

This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of treatment with Camrelizumab (SHR-1210) + definitive chemoradiotherapy(dCRT) vs placebo+dCRT for locally advanced esophageal cancer patients in China. Camrelizumab (SHR-1210) is a humanized anti-PD1 IgG4 monoclonal antibody.

Description

In this study, eligible subjects will be randomized into study arm or control arm. Participants receive camrelizumab or placebo + chemotherapy + radiation therapy . The chemotherapy regimens are : paclitaxel plus cisplatin Progression-free survival (PFS) assessed by the Independent Review Committee (IRC) will be the primary outcomes.

Details
Condition Esophageal Diseases, Esophageal Cancer, Esophageal Cancer, head and neck cancer, head and neck cancer
Age 18-75 years
Treatment Placebo, Paclitaxel, Cisplatin, Radiation, Camrelizumab
Clinical Study IdentifierNCT04426955
SponsorJiangsu HengRui Medicine Co., Ltd.
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

18 to 75 years; 2.Histologically confirmed diagnosis of localized ESCC
Measurable and/or non-measurable disease defined per RECIST v1.1; 4.ECOG
Performance Status 1; 5.Adequate organ function

Exclusion Criteria

Indicators of severe malnutrition
A history of surgery for esophageal cancer
Clinically uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention
Known to be intolerable or resistant to treatment with the protocol-specified chemotherapy
Received prior chemotherapy, radiotherapy, targeted therapy or immune-oncology therapies
Active autoimmune diseases or history of autoimmune diseases that may relapse
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.